ArticleCNS neuroscience & therapeutics2019
Costimulatory checkpoint SLAMF8 is an independent prognosis factor in glioma.
Article in CNS neuroscience & therapeutics, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 28 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
28 citing papers in PubMed, 38 citations in OpenAlex.
- SLAMF8 promotes tumor growth of gastric cancer by enhancing M2 polarization of tumor-associated macrophages.Journal of translational medicine · 2026Article
- SLAMF8 Promotes M2 Polarization of Macrophages and Enhances Breast Cancer Proliferation.Breast cancer (Dove Medical Press) · 2026Article
- Inhibiting SLAMF8 modulates tumor-associated macrophages and restores CD8+ T cell-mediated antitumor immunity in colorectal cancer.Oncoimmunology · 2025Article
- Mechanistic insights into SLAMF8-mediated prostate cancer metastasis via the TLR4-NF-κB pathway.Journal of translational medicine · 2025Article
- SLAMF8 expression and prognostic significance in melanoma: A multi-omics and Mendelian randomization study.Cancer biomarkers : section A of Disease markers · 2025Observational
- Identifying survival subtypes with autoencoder using multiple types of high-dimensional genomic data from studies of glioblastoma multiforme.Briefings in bioinformatics · 2025Article
- SLAMF receptors: key regulators of tumor progression and emerging targets for cancer immunotherapy.Molecular cancer · 2025Review
- SLAM family-mediated crosstalk between tumor and immune cells in the tumor microenvironment: a promising biomarker and a potential therapeutic target for immune checkpoint therapies.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2025Review
- Comprehensive analysis of signaling lymphocyte activation molecule family as a prognostic biomarker and correlation with immune infiltration in clear cell renal cell carcinoma.Oncology letters · 2024Article
- SLAMF8 can predict prognosis of pan-cancer and the immunotherapy response effectivity of gastric cancer.Aging · 2024Article
- In Silico Analysis Highlights Potential Predictive Indicators Associated with Secondary Progressive Multiple Sclerosis.International journal of molecular sciences · 2024Article
- Signaling lymphocytic activation molecule family receptors as potential immune therapeutic targets in solid tumors.Frontiers in immunology · 2024Review
- A Blood-Based Immune Gene Signature with Prognostic Significance in Localized Prostate Cancer.Cancers · 2023Article
- SLAMF8, a potential new immune checkpoint molecule, is associated with the prognosis of colorectal cancer.Translational oncology · 2023Article
- Role of signaling lymphocytic activation molecule family of receptors in the pathogenesis of rheumatoid arthritis: insights and application.Frontiers in pharmacology · 2023Review
- Protein disulfide isomerase A3 as novel biomarker for endometrial cancer.Frontiers in oncology · 2023Article
- SLAM-family receptors come of age as a potential molecular target in cancer immunotherapy.Frontiers in immunology · 2023Review
- A pan-cancer analysis reveals the diagnostic and prognostic role of CDCA2 in low-grade glioma.PloS one · 2023Article
- Novel Inflammasome-Based Risk Score for Predicting Survival and Efficacy to Immunotherapy in Early-Stage Non-Small Cell Lung Cancer.Biomedicines · 2022Article
- Exploring the Change of Host and Microorganism in Chronic Obstructive Pulmonary Disease Patients Based on Metagenomic and Metatranscriptomic Sequencing.Frontiers in microbiology · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
aimsImmune checkpoint blockade has made breakthroughs in immunotherapy for glioma. However, current immunotherapy has therapeutic benefits only in a subset of patients and accompanied by immune-related side effects. SLAMF8 is a costimulatory molecule that affects the activation of macrophages in inflammation. The study of SLAMF8 may provide new information for immunological research and treatment of glioma.
methodsCGGA and TCGA cohorts of 946 patients with RNA sequencing data and full clinical information were analyzed using R language and GraphPad Prism 7.
resultsSLAMF8 was overexpressed along with malignancy progression and was a biomarker of mesenchymal subtype. As an independent prognostic factor, high SLAMF8 conferred reduced overall survival and chemotherapy resistance. SLAMF8 implied lower proportion of cancer cells along with increasing enrichment of monocytic lineage, myeloid dendritic cells. Functional analysis showed higher SLAMF8 indicated activation of antigen processing and presenting and the IFN-γ/TNF/TLR-mediated signaling. Meanwhile, coexpressing with classical checkpoint SLAMF8 aggravated immunosuppression and enhanced inflammation response.
conclusionOur study highlighted the important role of SLAMF8 in malignancy progression, shortened survival, and immune disorders. Further research on SLAMF8 in immunosuppression and inflammation response to glioma cells could aid immunotherapy for glioma.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.